Actionable news
All posts from Actionable news
Actionable news in AMGN: Amgen Inc.,

FDA rejects Amgen's Parsabiv NDA for secondary hyperparathyroidism; shares down 1% premarket

Amgen (NASDAQ:AMGN) is down 1% premarket on light volume in response to its announcement that it received a Complete Response Letter (CRL) from the FDA related to its New Drug Application (NDA) seeking approval of Parsabiv (etelcalcetide) for the treatment of secondary hyperparathyroidism (sHPT) in adult patients with chronic...